12:00 AM
 | 
Oct 04, 1999
 |  BC Week In Review  |  Clinical News  |  Regulatory

Enhanced pretargeting method regulatory update

IMMU received U.S. Patent No. 5,958,408 covering the use of a clearing agent such as an anti-idiotype antibody or...

Read the full 71 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >